In terms of GLP1-RAs, in a randomized controlled trial comparing liraglutide 3.0 mg with placebo (both as lifestyle modification adjuncts) on BMI reduction among 251 12 to <18 year olds with obesity (BMI ≥ 95th percentile), mean 56-week placebo-subtracted change in %BMIp95 was 6.2 percentage points (relative placebo-subtracted percent reduction in BMI 4.6%) (29). Here, GLP1R is linked to obesity disorder.